ASCO 2024 Abstract for Trial #21-39

Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click above link to view abstract, login required to view video.

Click to view ASCO 2024 Presentation for Trial 21-39.

Related Abstracts

Discover more abstracts for our trials.

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider

Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

Sep 24, 2024

Dr. Reva Schneider

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

Sep 24, 2024

Dr. Douglas Orr
See All Posts